Sunday, May 11, 2025 5/11/2025

Development of CapCell Scope for Metabolic Imaging of Tissue Heterogeneity and Therapy Response

Award Number: R01EB028148
ORGANIZATION: NATIONAL INSTITUTE Of BIOMEDICAL IMAGING & BIOENGINEERING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Description

Development of CapCell Scope for Metabolic Imaging of Tissue Heterogeneity and Therapy Response - Targeting and quantifying metabolic changes non-invasively is a powerful approach to facilitate diagnosis and evaluate therapeutic response. Cellular metabolism involves a vital network of pathways for homeostasis, growth, and survival and can shift from one nutrient pathway to another based on the extent of perfusion available to the cells. Interest in cellular metabolism and tissue vasculature continues to expand across a broad range of disciplines including neuroscience, cardiovascular biology, and the field of cancer research. Though there are many bench-top microscopes and metabolic tools available to provide exquisite resolution and contrast for metabolic or vascular imaging, these systems require extensive training and often have fields of view (FOV), resolution, and wavelengths that fit only the most common use cases. Further, they require researchers to transport animals to specialized facilities, and this limits access to longitudinal imaging. Additionally, there are surprisingly few biomedical imaging technologies available to image both the global landscape and local spatial variations of metabolic and vascular hallmarks in vivo. We propose to develop an optical imaging platform the Capillary-Cell or CapCell to permit studies of metabolic reprogramming and heterogeneity across the laboratory to clinical continuum. This technology will report on the major axes of metabolism, blood vessel architecture and morphology of different biological systems including organoids and xenograft mouse models. Our work will lead to the establishment of predictive biomarkers to support drug development, inform on drug choices and evaluate the efficacy of drugs in bench research and in patients. The technology will be portable and turnkey and therefore can be placed in individual labs instead of a central dedicated facility. This is essential to putting new biomarker capabilities directly into the hands of laboratory scientists. The clinical translatability of the CapCell will focus on breast cancer therapies. The CapCell will inform the selection of compounds for personalized management of cancer patients in adaptive clinical trials and ultimately those in a standard clinical setting. Further, it will enable the identification of successful drugs early in their development, thereby accelerating market approval for candidate therapies. Lastly, this technology will be instrumental in understanding metabolic heterogeneity during primary cancer formation and invasion and its modulation by oncogenic driver mutations and their inhibition. The biological models will include human organoids and mouse models developed at UCSF. Patient-derived organoids (PDO) will serve as a bridge between patients and mouse models – they can be created from patient samples, and they can then be engrafted into mice, and Patient-derived xenografts (PDX) models can be used to identify dynamic biomarkers associated with the risk of recurrence.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $591,384 )
2025	2025	DUKE UNIVERSITY	2200 W MAIN ST	DURHAM	NC	27705	DURHAM	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	6	4/18/2025	NON-COMPETING CONTINUATION	$591,384
														Subtotal = $591,384

Issue Date FY: 2024 ( Subtotal = $608,401 )
2024	2024	DUKE UNIVERSITY	2200 W MAIN ST	DURHAM	NC	27705	DURHAM	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	001	5	7/18/2024	COMPETING CONTINUATION	$608,401
2024	2022	DUKE UNIVERSITY	2200 W MAIN ST	DURHAM	NC	27705	DURHAM	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	4	10/19/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $608,401

Issue Date FY: 2022 ( Subtotal = $565,303 )
2022	2022	DUKE UNIVERSITY	2200 W MAIN ST STE 710	DURHAM	NC	27708	DURHAM	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	001	4	6/27/2022	NON-COMPETING CONTINUATION	$56,529
2022	2022	DUKE UNIVERSITY	2200 W MAIN ST STE 710	DURHAM	NC	27708	DURHAM	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	4	12/15/2021	NON-COMPETING CONTINUATION	$508,774
														Subtotal = $565,303

Issue Date FY: 2021 ( Subtotal = $563,937 )
2021	2021	DUKE UNIVERSITY	2200 W MAIN ST STE 710	DURHAM	NC	27708	DURHAM	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	003	3	7/28/2021	NON-COMPETING CONTINUATION	$0
2021	2021	DUKE UNIVERSITY	2200 W MAIN ST STE 710	DURHAM	NC	27708	DURHAM	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	001	3	3/26/2021	NON-COMPETING CONTINUATION	$46,035
2021	2021	DUKE UNIVERSITY	2200 W MAIN ST STE 710	DURHAM	NC	27708	DURHAM	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	002	3	5/31/2021	NON-COMPETING CONTINUATION	$0
2021	2021	DUKE UNIVERSITY	2200 W MAIN ST STE 710	DURHAM	NC	27708	DURHAM	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	3	12/21/2020	NON-COMPETING CONTINUATION	$517,902
														Subtotal = $563,937

Issue Date FY: 2020 ( Subtotal = $576,841 )
2020	2020	DUKE UNIVERSITY	2200 W MAIN ST STE 710	DURHAM	NC	27708	DURHAM	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	2	1/16/2020	NON-COMPETING CONTINUATION	$576,841
														Subtotal = $576,841

Issue Date FY: 2019 ( Subtotal = $544,076 )
2019	2019	DUKE UNIVERSITY	2200 W MAIN ST STE 710	DURHAM	NC	27708	DURHAM	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	001	1	9/4/2019	NEW	$0
2019	2019	DUKE UNIVERSITY	2200 W MAIN ST STE 710	DURHAM	NC	27708	DURHAM	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	1	3/25/2019	NEW	$544,076
														Subtotal = $544,076

Grand Total All Awards = $3,449,942

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of CapCell Scope for Metabolic Imaging of Tissue Heterogeneity and Therapy Response

Award Number: R01EB028148

ORGANIZATION: NATIONAL INSTITUTE Of BIOMEDICAL IMAGING & BIOENGINEERING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer